Research Reveals Two Forms of Metastatic Prostate Cancer
University of Wisconsin–Madison scientists have identified two subtypes of metastatic prostate cancer that respond differently to treatment, information that could one day guide clinicians in treating patients with the therapies targeted to their disease. Read more.

First CDK4/6 Inhibitor for HR+ HER2– High-Risk BC
Eli Lilly announced that the FDA approved Verzenio (abemaciclib) in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2-), node-positive, early breast cancer at high risk of recurrence. Read more.  

Test Your Knowledge of Ovarian Cancer
Take a quiz to assess your understanding of treatment modalities for ovarian cancer, which ranks fifth in cancer deaths among women. Then, see how your answers measure up against the responses of your peers. Click here to begin the quiz.